Celgene (CELG) Revlimid Slows Myeloma Progression after Stem Cell Transplant Proactive Investors USA & Canada However, maintenance therapy with Revlimid® (lenalidomide) did … reduce the risk of myeloma progression or death by 60% among patients who had undergone an autologous stem cell transplant. These updated results from a P3 clinical trial were ... |
